Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksARIX.L Regulatory News (ARIX)

  • There is currently no data for ARIX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Team changes

6 Jul 2021 07:01

Arix Bioscience PLC (ARIX) Team changes 06-Jul-2021 / 07:00 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.


 

Arix Bioscience plc

 

Team changes

 

LONDON, 06 July 2021: Arix Bioscience plc ("Arix" or "the Company") (LSE: ARIX), a global venture capital company focused on investing and building breakthrough biotech companies, today announces that Mark Chin will be re-joining the Arix investment team as a Managing Director effective immediately.

 

Mark previously spent four years at Arix from 2016 to 2020 as an Investment Director. Mark sourced and led deals in key Arix portfolio companies, including: VelosBio (acquired by Merck for $2.75bn), Amplyx Pharmaceuticals (acquired by Pfizer), Aura Biosciences, Harpoon Therapeutics (Nasdaq IPO) and Imara (Nasdaq IPO). He has extensive venture capital expertise in early to late stage investing and significant experience as a board member, of both private and public companies in the US and Europe. Since leaving Arix in 2020, Mark has remained a director of Harpoon Therapeutics, Inc. (Nasdaq: HARP), Imara Inc. (Nasdaq: IMRA) and Iterum Therapeutics plc (Nasdaq: ITRM). Mark is based in New York and will work to source and evaluate new investment opportunities and support existing venture investments through to exit.

 

Dr. Christian Schetter, Managing Director, has resigned from the investment team and will leave the Company on 31 August 2021. Dr. John Cassidy, Principal, had previously resigned from the investment team and will leave the Company on 30 July 2021. Following the changes announced on 30 April 2021, the Board continues to develop the Company's strategy and evaluate the appropriate team structure. The Board will work closely with Mark Chin to rebuild the Company's investment team, adding new talent to deploy investment capital and manage the Company's existing portfolio.

 

After five years at Arix, Marcus Karia, Group Finance Director, will leave the Company later this year to pursue other opportunities. Marcus will continue in his role until a search for his successor is completed.

 

Robert Lyne, Interim CEO of Arix, commented: "I am very pleased to welcome Mark back to Arix. Mark is a talented investor and has played an instrumental role in the development of Arix, identifying and leading a number of high quality investments, which have made a significant contribution to the strong performance across Arix's portfolio. Mark will work closely with the Board to determine Arix's future investment strategy and will play a pivotal role in building the investment team and shaping the Company's future.

 

"On behalf of the Company I would like to thank Christian, John and Marcus for their valuable contribution to Arix. We wish them all the best for the future."

 

Mark Chin, Managing Director at Arix, added: "Biotech is now recognised as one the most important sectors to society: the vaccine response to the pandemic and recent breakthroughs in oncology and other diseases underscore its disruptive potential. Having seen first-hand the novel technologies Arix has fueled, and with the significant capital available to us, I am excited to help identify and build the next generation of innovative biotech companies based on cutting-edge science and world-class leadership."

 

Peregrine Moncreiffe, Chairman of Arix, commented: "The Board is determined to optimise Arix's contribution to the biotech sector in Europe and the US and believes that its reconstituted investment team will generate superior risk-adjusted returns for our shareholders."

[ENDS]

 

Enquiries

For more information on Arix, please contact:

 

Arix Bioscience plc

Charlotte Parry, Head of Investor Relations

+44 (0)20 7290 1072

charlotte@arixbioscience.com

 Optimum Strategic Communications

Mary Clark, Manel Mateus

+44 (0)20 3922 1906

optimum.arix@optimumcomms.com

 

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.

 

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

 

 


ISIN:GB00BD045071
Category Code:MSCH
TIDM:ARIX
LEI Code:213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.:115436
EQS News ID:1215445
 
End of AnnouncementEQS News Service

UK Regulatory announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
3rd Dec 20187:00 amPRNAutolus announces update on AUTO4 and AUTO5 programmes
15th Nov 20187:00 amPRNPositive Phase 1 clinical trial results
12th Nov 20187:00 amPRNArix invests in $70m Harpoon Series C investment round
2nd Nov 201811:33 amPRNAutolus Therapeutics to Present New Data at the ASH
30th Oct 20182:11 pmPRNAura Biosciences reports positive Phase 1b/2 data
24th Oct 20187:00 amPRNLogicBio announces closing of initial public offering
19th Oct 20187:00 amPRNLogicBio prices Nasdaq IPO
10th Oct 20187:00 amPRNUpdate on LogicBio proposed IPO in the United States
1st Oct 20187:00 amPRNCo-leads $58 million Series A for VelosBio
26th Sep 20187:00 amPRNLogicBio files registration for proposed IPO in the US
18th Sep 20182:00 pmPRNUpdate on Iterum Therapeutics Phase 3 trials
12th Sep 20184:30 pmPRNAnnounces Board Changes
10th Sep 20184:24 pmPRNHolding(s) in Company
4th Sep 20187:00 amPRNChanges announced to executive team
17th Aug 20181:01 pmPRNHoldings in Company and Lock-in Agreement
10th Aug 20187:01 amPRNPositive clinical progression in Group Businesses
10th Aug 20187:00 amPRNArtios completes £65m Series B investment round
6th Aug 20187:00 amPRNArix Bioscience announces first VIPE investment
30th Jul 20187:00 amPRNInterim Results for the Six Months Ended 30 June 2018
25th Jul 20184:41 pmPRNNotice of Results
2nd Jul 20181:16 pmPRNTotal Voting Rights
26th Jun 20185:30 pmPRNAutolus annouces closing of IPO
22nd Jun 20187:07 amPRNAutolus Announces Pricing of Initial Public Offering
21st Jun 201810:22 amPRNIssue of Shares, Total Voting Rights & PDMR Notification
11th Jun 20184:23 pmPRNDirector/PDMR Shareholding
8th Jun 201811:36 amPRNUpdate on Autolus proposed NASDAQ IPO
31st May 20182:00 pmPRNLord John Hutton steps down from Board of Directors
30th May 20184:13 pmPRNIterum Therapeutics plc Closes Initial Public Offering
25th May 20187:19 amPRNIterum Therapeutics plc Prices Initial Public Offering
17th May 201812:29 pmRNSResult of AGM
17th May 20187:00 amRNSUpdate on Iterum proposed NASDAQ IPO
8th May 20187:00 amRNSAutolus Files for Proposed US IPO
2nd May 201810:10 amRNSArix notes Iterum?s proposed US IPO
23rd Apr 20187:00 amRNSAnnual Results 2017
16th Apr 20187:25 amRNSNotice of Annual Results
5th Apr 20187:00 amRNSArix to present at HC Wainwright on 10 April
4th Apr 20189:01 amRNSHolding(s) in Company
4th Apr 20189:00 amRNSTotal Voting Rights
26th Mar 20181:40 pmRNSHolding(s) in Company
26th Mar 201812:31 pmRNSArix notes positive Ph2b COPD data from Verona
23rd Mar 20189:00 amRNSHolding(s) in Company
22nd Mar 201811:51 amRNSHolding(s) in Company
21st Mar 201812:46 pmRNSHoldings in Company
21st Mar 201811:40 amRNSDirector/PDMR Shareholding
21st Mar 201811:39 amRNSHolding(s) in Company
16th Mar 201811:45 amRNSResults of General Meeting
16th Mar 20187:00 amRNSResults of Capital Raising
6th Mar 20187:00 amRNSArix notes Autolus's potential US IPO
28th Feb 201811:29 amRNSPublication of a Prospectus
28th Feb 20187:00 amRNSProposed Firm Placing, Placing and Offer

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.